KOL | Jonathan Paul PicciniDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA | Section of Cardiac Electrophysiology, Division of Cardiovascular Disease, Duke ... |
KOL Resume for Jonathan Paul Piccini
| Year | |
|---|---|
| 2022 | Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA |
| 2021 | Division of Cardiology, Duke University Medical Center, Durham, North Carolina, USA Duke Clinical Research Institute, Durham, NC (M.W.S., S.V., Z.L., J.P., J.K.H., A.N.V., E.D.P.). |
Jonathan Paul Piccini: Influence Statistics
| Concept | World rank |
|---|---|
| afb afb 6 | #1 |
| arrhythmia recurrence dm | #1 |
| findings dedicated mdct | #1 |
| micra implantation patients | #1 |
| avc status | #1 |
| women crt defibrillators | #1 |
| ablation women | #1 |
| p0001 crt pacemakers | #1 |
| effective programming atp | #1 |
| discrimination apple score | #1 |
| 076 95 ablation | #1 |
| fibrillation treated | #1 |
| costs repeat ablation | #1 |
| hrdd hred | #1 |
| sgb median | #1 |
| death continuous monitoring | #1 |
| prescriptions ≥50 | #1 |
| afb 6 | #1 |
| periprocedural imaging | #1 |
| 40 cardiac amyloid | #1 |
| orbitaf | #1 |
| transvenous vvi pacemakers | #1 |
| procedure characteristics outcomes | #1 |
| risk adverse bleeding | #1 |
| contraindications anticoagulant | #1 |
| patients sies | #1 |
| score poaf score | #1 |
| mortality nonprecluded patients | #1 |
| heart rhythm disorders | #1 |
| 1 point obesity | #1 |
| discrimination recurrent | #1 |
| behavior synchrony | #1 |
| aad amiodarone | #1 |
| esrd oac | #1 |
| endocarditis persistent bacteremia | #1 |
| synchrony leadless pacemaker | #1 |
| male pacemaker death | #1 |
| amiodarone incident cancer | #1 |
| single ablation pvicfae | #1 |
| implantation cied | #1 |
| adjunctive lesion | #1 |
| increased rotor | #1 |
| progression afb | #1 |
| transvenous vvi | #1 |
| tracking atrial mechanical | #1 |
| increased risk cardioembolism | #1 |
| procedure characteristics | #1 |
| european association sca | #1 |
| sotalol ablation | #1 |
| sinus rhythm block | #1 |
Open the FULL List in Excel | |
Prominent publications by Jonathan Paul Piccini
AIMS: Vascular disease is included in a risk scoring system to predict stroke in patients with non-valvular atrial fibrillation (AF). This post hoc analysis of ROCKET AF aimed to determine the absolute rates of stroke and bleeding, and the relative effectiveness and safety of rivaroxaban vs. warfarin in patients with and without peripheral artery disease (PAD). Peripheral artery disease was defined on the case-report form as the presences of intermittent claudication, amputation for ...
| Known for Patients Pad | Peripheral Artery Disease | Rivaroxaban Warfarin | Atrial Fibrillation | Systemic Embolism |
Atrial fibrillation (AF) is a major worldwide public health problem, and AF in association with valvular heart disease (VHD) is also common. However, management strategies for this group of patients have been less informed by randomized trials, which have largely focused on 'non-valvular AF' patients. Thrombo-embolic risk also varies according to valve lesion and may also be associated with CHA2DS2VASc score risk factor components, rather than only the valve disease being causal. Given ...
| Known for Valvular Heart Disease | European Society | Patients Vhd | Atrial Fibrillation | Heart Rhythm |
IMPORTANCE: The benefits of cardiac resynchronization therapy (CRT) in clinical trials were greater among patients with left bundle-branch block (LBBB) or longer QRS duration.
OBJECTIVE: To measure associations between QRS duration and morphology and outcomes among patients receiving a CRT defibrillator (CRT-D) in clinical practice.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of Medicare beneficiaries in the National Cardiovascular Data Registry's ICD Registry between ...
| Known for Qrs Duration | Heart Failure | Patients Lbbb | Resynchronization Therapy | Branch Block |
Importance: Catheter ablation is effective in restoring sinus rhythm in atrial fibrillation (AF), but its effects on long-term mortality and stroke risk are uncertain.
Objective: To determine whether catheter ablation is more effective than conventional medical therapy for improving outcomes in AF.
Design, Setting, and Participants: The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation trial is an investigator-initiated, open-label, multicenter, randomized trial ...
| Known for Catheter Ablation | Drug Therapy | Atrial Fibrillation | Cardiac Arrest | Death Stroke |
BACKGROUND: Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). This prespecified secondary analysis compares outcomes in older and younger ...
| Known for Atrial Fibrillation | Direct Factor | Warfarin Rivaroxaban | Oral Aged Aged | Embolism Trial |
BACKGROUND: The prevalence of both atrial fibrillation (AF) and diabetes mellitus (DM) are rising, and these conditions often occur together. Also, DM is an independent risk factor for stroke in patients with AF. We aimed to examine the safety and efficacy of rivaroxaban vs warfarin in patients with nonvalvular AF and DM in a prespecified secondary analysis of the ROCKET AF trial.
METHODS: We stratified the ROCKET AF population by DM status, assessed associations with risk of outcomes by ...
| Known for Patients Dm | Atrial Fibrillation | Rivaroxaban Warfarin | Efficacy Safety | Direct Factor |
Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial
[ PUBLICATION ]
OBJECTIVES: This study sought to investigate the outcomes following cardioversion or catheter ablation in patients with atrial fibrillation (AF) treated with warfarin or rivaroxaban.
BACKGROUND: There are limited data on outcomes following cardioversion or catheter ablation in AF patients treated with factor Xa inhibitors.
METHODS: We compared the incidence of electrical cardioversion (ECV), pharmacologic cardioversion (PCV), or AF ablation and subsequent outcomes in patients in a post ...
| Known for Rivaroxaban Warfarin | Cardioversion Ablation | Atrial Fibrillation | Stroke Patients | Systemic Embolism |
Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation
[ PUBLICATION ]
Importance: Catheter ablation is more effective than drug therapy in restoring sinus rhythm in patients with atrial fibrillation (AF), but its incremental effect on long-term quality of life (QOL) is uncertain.
Objective: To determine whether catheter ablation is more beneficial than conventional drug therapy for improving QOL in patients with AF.
Design, Setting, and Participants: An open-label randomized clinical trial of catheter ablation vs drug therapy in 2204 symptomatic patients ...
| Known for Catheter Ablation | Atrial Fibrillation | Medical Therapy | 12 Months | Quality Life |
BACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin.
METHODS: In a double-blind trial, we randomly assigned 14,264 patients with nonvalvular atrial fibrillation who were at increased risk for stroke to receive either rivaroxaban (at a daily dose of 20 mg) or ...
| Known for Atrial Fibrillation | Year Warfarin | Primary Point | Stroke Rivaroxaban | Fatal Bleeding |
OBJECTIVES: The purpose of this study was to understand the possible risk of discontinuation in the context of clinical care.
BACKGROUND: Rivaroxaban is noninferior to warfarin for preventing stroke in atrial fibrillation patients. Concerns exist regarding possible increased risk of stroke and non-central nervous system (CNS) thromboembolic events early after discontinuation of rivaroxaban.
METHODS: We undertook a post-hoc analysis of data from the ROCKET AF (Rivaroxaban Once-Daily, ...
| Known for Atrial Fibrillation | Direct Factor | Rivaroxaban Stroke | Embolism Trial | Warfarin Patients |
Importance: The left atrial appendage is a key site of thrombus formation in atrial fibrillation (AF) and can be occluded or removed at the time of cardiac surgery. There is limited evidence regarding the effectiveness of surgical left atrial appendage occlusion (S-LAAO) for reducing the risk of thromboembolism.
Objective: To evaluate the association of S-LAAO vs no receipt of S-LAAO with the risk of thromboembolism among older patients undergoing cardiac surgery.
Design, Setting, and ...
| Known for Cardiac Surgery | Atrial Fibrillation | Allcause Mortality | Lower Risk | Appendage Occlusion |
Retrograde ascending aortic dissection as an early complication of thoracic endovascular aortic repair
[ PUBLICATION ]
OBJECTIVE: Retrograde ascending aortic dissection (rAAD) is a potential complication of thoracic endovascular aortic repair (TEVAR), yet little data exist regarding its occurrence. This study examines the incidence, etiology, and outcome of this event.
METHODS: A prospective institutional database was used to identify cases of acute rAAD following TEVAR from a cohort of 309 consecutive procedures from March 2005 (date of initial Food and Drug Administration approval) to September 2010. ...
| Known for Ascending Aortic | Dissecting Aorta | Proximal Landing Zone | Incidence Raad | Thoracic Endovascular |
Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
[ PUBLICATION ]
OBJECTIVES: We sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation (AF).
BACKGROUND: Dronedarone is a noniodinated amiodarone congener developed to maintain sinus rhythm. Few data are available to directly compare the efficacy and safety of dronedarone versus amiodarone.
METHODS: We conducted a systematic overview of all randomized controlled trials in which the authors evaluated dronedarone or amiodarone for the ...
| Known for Sinus Rhythm | Dronedarone Amiodarone | Atrial Fibrillation | Comparative Efficacy | Topic Controlled Trials |
OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks.
DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent ...
| Known for Atrial Fibrillation | Mortality Stroke | Bleeding Risk | Patients Anticoagulation | Cha2ds2 Vasc |
BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown.
METHODS AND RESULTS: We studied patterns of dabigatran use among patients enrolled in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry between June 2010 and August 2011 and followed for 12 months. Among 9974 atrial fibrillation patients included, 1217 (12%) were ...
| Known for Atrial Fibrillation | Dabigatran Patients | Outcomes Registry | Informed Treatment | United States |
Key People For Atrial Fibrillation
Jonathan Paul Piccini:Expert Impact
Concepts for whichJonathan Paul Piccinihas direct influence:Atrial fibrillation, Heart failure, Catheter ablation, Patients atrial fibrillation, Outcomes registry, Informed treatment, Rivaroxaban warfarin, Rhythm control.
Jonathan Paul Piccini:KOL impact
Concepts related to the work of other authors for whichfor which Jonathan Paul Piccini has influence:Atrial fibrillation, Heart failure, Oral anticoagulants, Catheter ablation, Stroke prevention, Major bleeding, Warfarin patients.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |